RKRakesh Khator

Rakesh Khator

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rakesh Khator has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Recent progress in the synthetic and medicinal perspective of imidazo[2,1- b ]thiazole derivatives

    by Virendra Santosh Amrutkar, Rakesh Khator, Vikramdeep Monga

    Imidazo[2,1-b]thiazole represents a privileged heterocyclic moiety in medicinal chemistry which garnered huge attention among the researchers because of its extensive biological properties and ease of synthetic feasibility. Substituted imidazo[2,1-b]thiazole analogs with diverse therapeutic outcomes play a crucial role in the cure or management of various human ailments. The impact of this moiety in drug discovery can be realized from the fact that drugs based on this scaffold are used clinically. Medicinal and synthetic chemists have widely explored the chemical space around this scaffold for the generation of novel molecules capable of interacting with different biological targets of therapeutic concern. Due to its fascinating pharmacological profile, chemists have unfolded different facile and efficient synthetic protocols for imidazo[2,1-b]thiazole-based molecules. The present review highlights its outstanding role in drug discovery including different approaches for the synthesis of imidazo[2,1-b]thiazole hybrids. The recent advancements in the medicinal chemistry of imidazo[2,1-b]thiazole based analogs along with structure-activity relationships (SARs) and molecular docking studies have been compiled. The present review provides valuable insights for the design and development of imidazo[2,1-b]thiazole based bioactive agents as potential therapeutic candidates with desired efficacy and safety profile.


  • Thiazolopyrimidine, a privileged scaffold: Recent updates on synthetic and pharmacological perspective in drug discovery

    by Rakesh Khator, Vikramdeep Monga

    Heterocyclic compounds are emerging as a privileged scaffold with a plethora of biological activities. In recent years, interest in thiazolopyrimidine chemistry has significantly increased due to its diverse pharmacological activities, such as anticancer, antimicrobial, analgesic, antioxidant, anti‐inflammatory, and so on. It provides various opportunities for structural modifications. The thiazolopyrimidine scaffold provides a key intermediate for the synthesis of various fused heterocycles and compounds of medicinal importance. By considering the role of this privileged scaffold, researchers have designed different synthetic protocols for the synthesis of thiazolopyrimidine derivatives. In the present review, several advancements in the synthetic methodology for the synthesis of thiazolopyrimidine derivatives with different substitutions have been discussed along with pharmacological activity, which provides key insights into the synthetic protocol and role of different substitutions on the core moiety for rational drug design and drug discovery.


  • Medicinal Aspects of PTP1B Inhibitors as Anti-Breast Cancer Agents: An Overview

    by Rakesh Khator, Avadh Biharee, Neha Bhatia, Swanand Kulkarni, Yogesh Singh, Chandrabose Karthikeyan, Akhlesh Kumar Jain, Suresh Thareja

    : Protein tyrosine phosphatase 1B (PTP1B) has gained interest as a therapeutic target for type 2 diabetes and obesity. Besides metabolic signalling, PTP1B is a positive regulator of signalling pathways linked to ErbB2-induced breast tumorigenesis. Substan-tial evidence proves that its overexpression is involved in breast cancer, which suggests that selective PTP1B inhibition might be effective in breast cancer treatment. Therefore, huge research is being carried out on PTP1B inhibitors and their activity against breast cancer development. To date, only two PTP1B inhibitors, viz. ertiprotafib and tro-dusquemine, have entered clinical trials. The discovery of selective inhibitors of PTP1B could open a new avenue in breast cancer treatment. In this review, we provide an exten-sive overview on the involvement of PTP1B in breast cancer, its pathophysiology, with special attention on the discovery and development of various natural as well as synthetic PTP1B inhibitors. This study will provide significant information to the researchers de-veloping PTP1B inhibitors for breast cancer treatment.


  • Identification of Novel Thiazolidinedione Based Pancreatic Lipase Inhibitors for the Management of Obesity Using In Silico Approach

    by Rakesh Khator, Yogesh Singh, Vivek Asati, Vikramdeep Monga

    Accumulation of excessive fat in the body is an indication of obesity, which is becoming an alarming health concern around the world. Pancreatic lipase has been found to have a promising role in the digestion of dietary fats thereby inhibition of pancreatic lipase can be a therapeutic strategy for the management of obesity. Literature showed the anti‐pancreatic lipase potential of thiazolidinediones thereby the current study is designed to identify substituted thiazolidinedione‐based molecules as pancreatic lipase inhibitors. A 3D QSAR model with R 2 value of 0.7283 and Stability of 0.843 was generated to determine the nature of substitution necessary for the inhibitory activity. Based on the generated 3D QSAR, the activity of 352 novel‐designed molecules was predicted and further screened through pharmacokinetic parameters. These compounds were docked into the binding site of the pancreatic lipase which led to the identification of 14 hit molecules with dock score between −9.523 to −7.604 kcal/mol. The molecular simulation studies and free energy calculation of the hit compounds i. e. 87 and 80 revealed good stability and binding in the active site of pancreatic lipase. The current study provides 14 hit molecules, which can be synthesized and further evaluated to explore their anti‐pancreatic lipase inhibitory activity.


  • Recent Advances in the Synthesis and Medicinal Perspective of Pyrazole-Based α-Amylase Inhibitors as Antidiabetic Agents

    by Rakesh Khator, Vikramdeep Monga

    Diabetes is a serious health threat across the globe, claiming millions of lives worldwide. Among the various strategies employed, inhibition of α-amylase is a therapeutic protocol for the manageme... Graphical abstract


  • Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction Inhibitors for the Treatment of Cancer

    by Neha Bhatia, Rakesh Khator, Swanand Kulkarni, Yogesh Singh, Pradeep Kumar, Suresh Thareja

    Discovery of MDM2 and MDM2-p53 interaction inhibitors changed the direction of anticancer research as it is involved in about 50% of cancer cases globally. Not only the inhibition of MDM2 but also its interaction with p53 proved to be an effective strategy in anticancer drug design and development. Various molecules of natural as well as synthetic origin have been reported to possess excellent MDM2 inhibitory potential. The present review discusses the pathophysiology of the MDM2-p53 interaction loop and MDM2/MDM2-p53 interaction inhibitors from literature covering recent patents. Focus has also been put on characteristic features of the active site of the target and its desired interactions with the currently FDA-approved inhibitor. The designing approach of previously reported MDM2/MDM2-p53 interaction inhibitors, their SAR studies, in silico studies, and the biological efficacy of various inhibitors from natural as well as synthetic origins are also elaborated. An attempt is made to cover recently patented MDM2/MDM2- p53 interaction inhibitors.